Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
8.0
194.74%
80%
—
469.02%
Every year
—
5 Years
Score8.0
Net Growth194.74%
Net Trend80%
Net Income Consistency—
Rev Growth469.02%
Rev TrendEvery year
Revenue Consistency—
Alnylam Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 492M to $ 3.71B and net income went from -$ 858M to $ 313M. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 41M to $ 3.71B and net income went from -$ 290M to $ 313M. Revenue increased in 9 of those 10 years; net income in 6.
Alnylam Pharmaceuticals Inc currently holds a 20-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 223.95 | — |
1 Year2025-08-12 | $ 429.93 | -47.91% |
5 Years2021-08-12 | $ 200.92 | 11.46% |
10 Years2016-08-12 | $ 74.08 | 202.31% |
20 Years2006-08-11 | $ 11.82 | 18x |
All Time2004-05-28 | $ 6.01 | 37x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time2004-05-28 |
|---|---|---|---|---|---|---|
| Price | $ 223.95 | $ 429.93 | $ 200.92 | $ 74.08 | $ 11.82 | $ 6.01 |
| Return | — | -47.91% | 11.46% | 202.31% | 18x | 37x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 4.80B | $ 807M | $ 3.30B |
| 2025 | $ 3.71B | $ 313M | $ 2.90B |
| 2024 | $ 2.24B | -$ 278M | $ 2.69B |
| 2023 | $ 1.82B | -$ 440M | $ 2.43B |
| 2022 | $ 1.03B | -$ 1.13B | $ 2.19B |
| 2021 | $ 844M | -$ 852M | $ 2.43B |
| 2020 | $ 492M | -$ 858M | $ 1.87B |
| 2019 | $ 219M | -$ 886M | $ 1.53B |
| 2018 | $ 74M | -$ 761M | $ 1.08B |
| 2017 | $ 89M | -$ 490M | $ 1.70B |
| 2016 | $ 47M | -$ 410M | $ 942M |
| 2015 | $ 41M | -$ 290M | $ 1.08B |
| 2014 | $ 50M | -$ 360M | $ 696M |
| 2013 | $ 47M | -$ 89M | $ 245M |
| 2012 | $ 66M | -$ 106M | $ 122M |
| 2011 | $ 82M | -$ 57M | $ 146M |
| 2010 | $ 100M | -$ 43M | $ 233M |
| 2009 | $ 100M | -$ 47M | $ 281M |
| 2008 | $ 96M | -$ 26M | $ 430M |
| 2007 | $ 50M | -$ 85M | $ 389M |
| 2006 | $ 26M | -$ 34M | $ 217M |
| 2005 | $ 5M | -$ 42M | $ 80M |
| IPO2004 | $ 4M | -$ 32M | $ 46M |
Explore beyond ALNY
You're looking at Alnylam Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
